| Biomarker ID | 923 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation Status Of CHST7; LMX1B; RAFTLIN; RASGRF2; TNFRSF10D; ZNF135 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Methylated with Clinical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | clinical recurrence Vs biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 4 different sub groups of patients with prostate cancer: (i) tumor (n = 158) versus matched normal tissues (n = 34), (ii) recurrence (n = 98) versus nonrecurrence (n = 60); (iii) clinical recurrence (n = 59) versus biochemical recurrence (n = 39); and (iv) systemic recurrence (n = 23) versus local recurrence (n = 36) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Methylation27 microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CHST7, LMX1B, RAFTLIN, RASGRF2, TNFRSF10D, ZNF135 |